Most of molecular and genetic markers are still lacking confirmation; currently, only two markers, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase1 (IDH1) mutations, are commonly accepted genetic biomarkers for patients with glioblastoma [37]. Here, IDH1 is linked to glioblastoma.